Policy Updates on Access to and Affordability of Innovative Medicines in China-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Policy Updates on Access to and Affordability of Innovative Medicines in China

Published:2022-07 Issue: Volume:30 Page:59-66
ISSN:2212-1099
Container-title:Value in Health Regional Issues
language:en
Short-container-title:Value in Health Regional Issues

Author:

Liu Gordon G.,Wu Jing,He Xiaoning,Jiang Yawen

Publisher

Elsevier BV

Subject

Health Policy,Pharmacology, Toxicology and Pharmaceutics (miscellaneous),Economics, Econometrics and Finance (miscellaneous)

Reference16 articles.

1. Unlocking access to novel medicines in China: a review from a health system perspective;Diao;Risk Manag Healthc Policy,2019

2. A policy study on NDA/BLA expedited pathways in China, US and EU;Ren;Chin J New Drugs,2020

3. Dying to survive and cancer care in China;Lucas;Lancet Oncol,2019

4. Reforming China’s drug regulatory system;Xu;Nat Rev Drug Discov,2018

5. The availability and affordability of orphan drugs for rare diseases in China;Gong;Orphanet J Rare Dis,2016

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Healthcare utilization and economics evaluation of paliperidone palmitate once-monthly in schizophrenia: a one-year, real-world, and retrospective mirror image study in China;Frontiers in Psychiatry;2024-09-04

2. Impact of competition on reimbursement decisions for cancer drugs in China: an observational study;The Lancet Regional Health - Western Pacific;2024-09

3. Sugemalimab combined with chemotherapy for the treatment of advanced esophageal squamous cell carcinoma: a cost-effectiveness analysis;Frontiers in Pharmacology;2024-06-28

4. List prices and clinical value of anticancer drugs in China, Japan, and South Korea: a retrospective comparative study;The Lancet Regional Health - Western Pacific;2024-06

5. Cost-effectiveness of additional serplulimab to chemotherapy in metastatic squamous non-small cell lung cancer patients;Frontiers in Immunology;2024-04-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3